Evidence map›Paper›PMID 32761446›Full record

ArticleNeurotoxicity research2020

Cell-Permeable Calpain Inhibitor SJA6017 Provides Functional Protection to Spinal Motoneurons Exposed to MPP

Supriti Samantaray, Varduhi H Knaryan, Angelo M Del Re, John J Woodward, Donald C Shields, Mitsuyoshi Azuma, Jun Inoue, Swapan K Ray, Naren L Banik

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotoxicity research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Supriti SamantarayDepartment of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas St., MSC606 Suite 301, Charleston, SC, 29425, USA.
Varduhi H KnaryanDepartment of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas St., MSC606 Suite 301, Charleston, SC, 29425, USA.
Angelo M Del ReDivision of Neuroscience Research and Center for Drug & Alcohol Programs, Medical University of South Carolina, Charleston, SC, USA.
John J WoodwardDivision of Neuroscience Research and Center for Drug & Alcohol Programs, Medical University of South Carolina, Charleston, SC, USA.
Donald C ShieldsDepartment of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas St., MSC606 Suite 301, Charleston, SC, 29425, USA.
Mitsuyoshi AzumaKobe Creative Center, Senju Pharmaceutical Corporation Limited, Kobe, 651-2241, Japan.
Jun InoueKobe Creative Center, Senju Pharmaceutical Corporation Limited, Kobe, 651-2241, Japan.
Swapan K RayDepartment of Pathology, Microbiology & Immunology, University of South Carolina School of Medicine, Columbia, SC, USA.
Naren L BanikDepartment of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas St., MSC606 Suite 301, Charleston, SC, 29425, USA. baniknl@musc.edu.
Medical University of South Carolina · USOregon Health & Science University · USSenju Pharmaceutical (Japan) · JPUniversity of South Carolina · US

Funding

TREATING ETHANOL WITHDRAWAL WITH LORAZEPAM/NALTREXONEP50AA010761 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HOWARD C. BECKER · 1996 to 2026
$46.8M
Extra-nigral Neurodegeneration in Experimental Parkinson's DiseaseR01NS062327 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BANIK, NAREN L · 2009 to 2013
$1.6M
Attenuation of Inflammatory Response in Progressive Neurodegeneration in Parkinson's DiseaseI01BX004269 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI BANIK, NAREN L, HAQUE, AZIZUL · 2019 to 2023
–
BLRD VA I01 BX004269NIAAA NIH HHS P50 AA010761NINDS NIH HHS R01 NS062327NINDS NIH HHS R01NS062327-01A2South Carolina State Spinal Cord Research Fund SCIRF-2015P-01, SCIRF-2015P-04, SCIRF-2015-I-01, SCIRF-2016 I-03, and SCIRF #2018 I-01U.S. Department of Veterans Affairs 1I01BX004269-01
6 · The paper itself

Abstract

Extra-nigral central nervous system sites have been found to be affected in Parkinson's disease (PD). In addition to substantia nigra, degeneration of spinal cord motor neurons may play a role in the motor symptoms of PD. To this end, hybrid rodent VSC 4.1 cells differentiated into motoneurons were used as a cell culture model following exposure to Parkinsonian neurotoxicant MPP

Indexed as

AnimalsApoptosisCalpainDipeptidesGlycoproteinsMotor NeuronsNeuroprotective AgentsReactive Oxygen SpeciesSpinal CordSubstantia NigraCalpaincalpain inhibitorsDipeptidesGlycoproteinsN-(4-fluorophenylsulfonyl)-L-valyl-L-leucinalNeuroprotective AgentsReactive Oxygen SpeciesApoptosisCalpainMotor proteinsOxidative stressParkinson’s

Identifiers

PMID32761446
PMCPMC9453439
OpenAlexW3048227633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.